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Abstract
Introduction: Vascular calcification is a risk factor for 
cardiovascular mortality in the general population. It 
is highly prevalent in end stage renal disease (ESRD) 
patients. Low magnesium (Mg) levels have been reported 
to have a strong association with vascular calcification 
in hemodialysis (HD) patients. The aims of this study 
were to evaluate the prevalence of vascular calcification 
and its relation to serum Mg concentration in a group of 
Egyptian HD patients.
Methods: We studied 65 stable patients undergoing 
maintenance HD for more than 6 months. Vascular 
calcification was evaluated using hand roentgenography. 
Serum Mg, phosphorus, corrected calcium and intact 
parathyroid hormone (iPTH) levels were compared 
between patients with and without vascular calcification.
Results: The study included 41 male and 24 female 
patients, aged 43-70 years. Vascular calcification was 
present in 38.5% of the patients. Mean serum Mg level 
was 2.88 ± 0.51 mg/dl. Male gender was more common 
in patients with vascular calcification, and they had 
significantly longer HD duration and significantly higher 
serum phosphorus and iPTH levels. Serum Mg level was 
significantly lower in patients with vascular calcification 
(2.36 ± 0.26 mg/dl vs.3.21 ± 0.32 mg/dl, p = 0.001). 
Serum Mg concentration remained as independent 
negative predictor of hand-artery vascular calcification 
after adjustment for age, gender, duration of HD, serum 
phosphorus and iPTH levels.
Conclusion: Vascular calcification is common in the 
study population and is associated with a lower serum 
Mg level. High or sustained-normal Mg levels may have 
a protective role against the development of vascular 
calcification in HD patients. 
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Introduction
Coronary artery calcification is an important predictor 
of cardiovascular mortality in the general population 
[1-3]. Atherosclerosis and vascular calcification are also 
associated with left ventricular hypertrophy (LVH) in 
hemodialysis (HD) patients and are important surrogate 
markers of cardiovascular mortality [4]. 
Vascular calcification in chronic renal failure (CRF) 
patients is characterized by diffuse mineral deposition, 
occurring predominantly in the media of the vessel, with 
no relationship to atheromatous plaque formation [5].  It 
primarily affects the aorta, but plain x-rays often show 
a characteristic tramline appearance of calcification 
extending to the peripheral small vessels, a finding 
confirmed histologically [5]. 
Among HD patients, arterial calcification density was 
found to increase with age, duration of hemodialysis, 
fibrinogen level, and the prescribed dose of calcium-
based phosphate binders [6]. It also correlates with 
duration of hypertension and total duration of renal 
disease [7]. Vascular calcification in CRF patients is 
also often associated with intimal proliferation [8], 
which in turn correlates with hyperparathyroidism and 
hyperphosphatemia [9], both common in ESRD.
Magnesium (Mg) is the fourth most abundant cation 
in the body, mainly located within bone and skeletal 
muscle. Normal serum Mg level has a narrow range of 
1.8-2.8 mg/dl. Approximately 60% of the total serum Mg 
is  present as free Mg ions, the biologically active form. 
The kidneys play a principal role in Mg balance in the 
healthy state. Approximately 70–80% of plasma Mg is 
filtered by the kidney, 95% of the filtered load of Mg is 
reabsorbed, and only 5% is excreted in the urine. As CRF 
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progresses, urinary Mg excretion may be insufficient to 
balance intestinal Mg absorption and dietary Mg intake 
becomes a major determinant of serum and total body 
Mg levels [10]. 
The serum Mg levels usually remain within normal limits 
until the glomerular filtration rate (GFR) drops to levels 
as low as 30 ml/min. At lower GFR levels, serum Mg level 
usually increases. Both hyper- and hypomagnesemia have 
deleterious consequences in CRF patients. Elevated Mg 
levels are associated with pruritus, and have potentially 
harmful effects on nerve conduction velocity, osseous 
metabolism and parathyroid gland function [11]. Various 
studies found a significant inverse correlation between 
serum Mg and intact parathyroid hormone (iPTH) 
levels [10]. Undue suppression of iPTH would result 
in mineralization defects and adynamic bone disease. 
Low Mg levels have been associated with impairment 
of myocardial contractility, intra-dialytic hemodynamic 
instability, and hypotension [11]. There is also evidence 
suggesting a significant role for hypomagnesemia in the 
pathogenesis of cardiovascular diseases in HD patients 
[12].
On the other hand, hypermagnesemia may play a 
protective role against the development and acceleration 
of arterial atherosclerosis in patients with chronic renal 
insufficiency [12], and magnesium supplements may 
play an important protective role against the progression 
of atherosclerosis in patients on dialysis [13]. 
Several studies found a significant inverse relationship 
between serum Mg and vascular calcification in HD 
patients [12, 14, 15]. In this study, we examined serum 
Mg levels and peripheral arterial calcification of the 
hand among a group of Egyptian non-diabetic patients 
undergoing maintenance HD. 
Methods
We recruited sixty five non-diabetic patients on 
maintenance HD for this study. All patients were on 
regular HD for more than 6 months and had no acute 
illness or malignancy at the time of the study. Patients 
were dialyzed with synthetic polysulfone membranes 
and  bicarbonate-based dialysate. The electrolytes 
concentration of dialysate fluid were as follows: sodium 
140 mmol/l, potassium 2.0 mmol/l, chloride 120 mmol/l, 
Mg 0.5 mEq/l (1.2 mg/dl), bicarbonate 30 mEq/l and 
calcium 1.25, 1.5 or 1.75 mmol/l according to the serum 
calcium–phosphate equilibrium. The duration of HD was 
individually tailored (~4 hours thrice weekly) to control 
body fluids and blood chemistries and to achieve a Kt/V 
> 1.2. Each subject gave informed written consent to 
participate in the study. Hand roentgenography was 
performed on each patient at a voltage of 45 kV. The 
hand roentgenographs were analyzed by a radiologist 
and the results were expressed as positive or negative 
according to the presence or absence of visible vascular 
calcification of the hand arteries distal to the wrist joints 
(figure 1).
Eight pre-dialysis non-fasting blood samples were drawn 
over a four months period prior to roentgenography to 
measure serum calcium, phosphate, Mg, and albumin 
levels. Serum calcium levels were corrected according 
to serum albumin levels. The mean values of these 
measurements were used for analysis. Serum iPTH was 
measured once at the time of roentgenography. Kt/V was 
calculated using the following formula: Kt/V = (0.026 x 
average urea reduction ratio) - 0.46
Continuous variables were expressed as mean ± SD. 
Unpaired Student’s t-test was used to compare clinical 
parameters between patients with and without vascular 
calcification, Chi-squared test was used to compare 
proportions. Multiple regression analysis was performed 
to explore the impact of serum Mg level on vascular 
calcification. All analyses were performed using SPSS 
17.0 for Windows on personal computers.
Figure 1: Plain X ray of the hand of a patient in group 1, 
showing visible calcification (arrows) of the hand arteries 
distal to the wrist
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Results
The study included 41 male and 24 female patients, with 
an age range of 22-77 years (mean 47.5 ± 15.4 years). 
Mean duration on dialysis was 25 ± 9 months and mean 
Kt/V was 1.46 ± 0.13. Clinical and biochemical profiles 
of the patients enrolled in the study are shown (Table 1). 
There were 25 patients (16 males and 9 females) with 
vascular calcification (group 1) and 40 patients (25 males 
and 15 females) without vascular calcification (group 2). 
There were no significant differences in age, smoking 
index, body mass index, diastolic blood pressure, serum 
calcium, serum albumin, serum creatinine or Kt/V between 
the two groups. Male gender was more common in group 
1 (vascular calcification), and patients in that group had 
significantly longer HD duration and significantly higher 
serum phosphorus and iPTH levels. On the other hand, 
serum Mg was significantly lower in group 1. 
Multiple regression analysis revealed that serum Mg 
concentration remained as an independent negative 
predictor of hand-artery vascular calcification in HD 
patients after adjustment for age, gender, duration of HD, 
serum phosphorus and iPTH level (Table 2).
Discussion
Radiographic surveys were previously used to evaluate 
vascular calcification in HD patients [15-18]. For the 
purpose of this study, vascular calcification was defined 
by the presence of visible arterial calcification of the 
hand arteries on plain roentgenographs. This method 
has limitations in terms of quantitative evaluation 
of calcification or detection of minute calcification. 
However, it is easily performed in clinical practice 
without the need for special equipment such as electron 
beam computed tomography. Using this method had 
revealed statistically significant associations between 
vascular calcification and different clinical parameters 
[15-18]. Some investigators examining factors affecting 
vascular calcification in HD patients have emphasized 
the importance of calcium-phosphate metabolism while 
neglecting the role of magnesium [18, 19]. In the present 
study, serum phosphate levels were significantly higher 
in patients with vascular calcification compared to those 
without, in agreement with previous investigations [13, 
15, 16, 18, 19].  Furthermore, we found that serum 
Mg concentrations were significantly lower in the 
vascular calcification group, and in multiple regression 
analysis, lower Mg concentration remained a significant 
independent predictor of the presence of vascular 
calcification after adjustment for other confounding 
factors, such as phosphate and iPTH. Our results are 
consistent with the several reports which showed that 
hypomagnesemia is significantly related to the presence 
of vascular calcification of the hand arteries, independent 
of serum phosphate and iPTH levels [13, 15, 16].
Concerning skeletal calcification, hypomagnesemia 
has been reported to be related to development of 
chondrocalcinosis in Bartter's,  Gateman’s  and short 
bowel syndromes [20].  Hypomagnesemia has also 
been reported to be related to development of ectopic 
Table 1:  Demographics and clinical characteristics of the studied patients groups with (group 1) and without (group 2) vascular 
calcification
Demographic and clinical characteristics Group 1 (n = 25) Group 2 (n = 40) P value
Age (years, mean ± SD) 57.2 ± 6.6 53.9  ± 7.3 0.07
Male gender (%) 64 62.5 0.04*
HD duration (months, mean ± SD) 36.4 ± 3.6 22.2 ± 7.3 0.001*
Smoking (%) 32 32.5 0.81
Body mass index (kg/m2, mean ± SD) 21.5 ± 2.8 20.9 ± 3.1 0.72
Serum albumin(g/dl, mean ± SD) 3.5 ± 0.5 3.6 ± 0.4 0.68
Serum creatinine (mg/dl, mean ± SD) 10.9 ± 1.8 10.7 ± 2.5 0.45
Hematocrit (%, mean ± SD) 30.5 ± 5.1 30.8 ± 4.5 0.9
Corrected serum calcium (mg/dl, mean ± SD) 9.3 ± 0.36 9.2 ± 0.35 0.6
Phosphorus (mg/dl, mean ± SD) 6.0 ± 0.64 4.95 ± 0.72 0.001*
Mg (mg/dl, mean ± SD) 2.36 ± 0.26 3.21 ± 0.32 0.001*
Intact parathyroid hormone (pg/ml, mean ± SD) 270 ± 45.6 187 ± 37.5 0.001*
* statistically significant
Arab Journal of Nephrology and Transplantation
16
Okasha, El Bendary and Mourad
calcification in animal models [21].  In the non-uremic 
general population, current literature showed strong 
evidence that hypomagnesemia is significantly associated 
with cardiovascular disease and atheromatous diseases 
[1-3].  In HD patients, intracellular and extracellular Mg 
has been reported to be negatively correlated with common 
carotid artery intima-media thickness, suggesting that 
Mg plays an important protective role in the development 
and acceleration of arterial atherosclerosis [12]. Serum 
Mg was previously reported to be significantly lower in 
peritoneal dialysis (PD) and HD patients with vascular 
calcification than in patients without calcification [13, 
15, 16]. Low serum Mg  was also reported to be related to 
a higher prevalence of mitral valve calcification among 
HD patients [14].  These observations raise the possibility 
that magnesium supplements may have a role in the 
prevention of vascluar calcification. An experimental 
study demonstrated that dietary supplementation with 
Mg reduced medial calcification of the grafted aorta in 
the rat [22]. Potential benefits have also been attributed 
to Mg carbonate use as an effective, less toxic and less 
expensive phosphate binder in HD patients [23].
These findings can be explained in the light of previous 
research. Mg acts as a cofactor in numerous enzyme 
systems, such as alkaline phosphatase, which was 
demonstrated to be present in the tissue of vascular 
calcification [24]. Mg concentration may affect 
alkaline phosphatase activity, leading to modulation 
of calcification mechanism in HD patients. Mg may 
affect phosphate crystal solubility in synovial fluid and 
serum Mg level may affect the development of vascular 
calcification reported to be closely related with inorganic 
phosphate [24].
Secondary hyperparathyroidism is frequently associated 
with soft tissue calcification, including vascular 
calcification. Wei et al found a significant inverse 
relationship between serum Mg and serum iPTH in 
HD and PD patients [10]. Navarro et al noted that 
hypermagnesemia was independently associated with 
decreased parathyroid hormone in PD patients [25].
Hypermagnesemia may protect against vascular 
calcification via a decrease in parathyroid hormone levels. 
In our study, parathyroid hormone levels were significantly 
higher in patients with vascular calcification, compared 
to those without calcification. In fact, the mean serum 
Mg concentration in the vascular calcification group was 
2.36 ± 0.26 mg/dl, i.e. within the normal reference range 
for normal subjects without renal failure. Dialysate Mg 
plays a critical role in maintaining Mg homeostasis in 
HD patients, with serum Mg being largely dependent on 
the concentration of the ion in the dialysis solution. We 
suggest that Mg concentration of dialysis fluid could be 
increased above the current concentration of  0.5 mmol/L 
(1.2 mg/dl), with the aim of  preventing or reducing 
vascular calcification in HD patients. However, further 
studies are required to determine what concentration of 
serum or dialysate Mg are optimal for these patients. 
Conclusion
The results of this study confirm previous observations 
that lower serum Mg levels are significantly associated 
with vascular calcification in HD patients, independent 
of the serum calcium, phosphate and iPTH levels. These 
results suggest that higher serum Mg concentrations may 
have a protective role against vascular calcification in 
HD  patients. Further studies are required to evaluate the 
role of raising Mg concentration of dialysis solutions in 
the context of preventing vascular calcification among 
HD  patients.
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